What is the recommended protocol for coronary CT angiography (CCTA) as the initial non‑invasive test in an adult with stable low‑ to intermediate‑risk chest pain, a normal resting ECG, and no known coronary artery disease?

Coronary CT Angiography (CCTA) Protocol for Stable Low-to-Intermediate Risk Chest Pain

For adults with stable chest pain, low-to-intermediate risk, normal resting ECG, and no known coronary artery disease, CCTA is the recommended first-line non-invasive test with Class I, Level A evidence for diagnosis of CAD, risk stratification, and guiding treatment decisions. 1

Initial Risk Assessment

• Begin by calculating pretest probability of obstructive CAD using a validated risk model (Risk Factor-weighted Clinical Likelihood model) 1
• Incorporate additional clinical data including peripheral artery examination, resting ECG findings, resting echocardiography results, and presence of vascular calcifications on prior imaging to refine the risk estimate 2
• CCTA is specifically recommended for patients with low or moderate (>5%-50%) pretest likelihood of obstructive CAD 2

CCTA as First-Line Test: The Evidence

The 2021 ACC/AHA guidelines provide the strongest recommendation (Class I, Level A) for CCTA in intermediate-high risk patients with stable chest pain and no known CAD, establishing it as effective for CAD diagnosis, risk stratification, and guiding treatment decisions 1. This recommendation is reinforced by:

• The 2024 ESC guidelines similarly recommend CCTA as first-line for patients with low or moderate pretest likelihood to diagnose obstructive CAD and estimate risk of major adverse cardiovascular events (MACE) 2
• CCTA demonstrates superior gatekeeping to invasive coronary angiography, with studies showing it avoids the need for ICA in 77% of patients otherwise referred for catheterization 3
• The DISCHARGE trial showed similar rates of major adverse cardiovascular events between CCTA and direct ICA strategies, but significantly fewer major procedure-related complications with CCTA (0.5% vs 1.9%, hazard ratio 0.26) 4

Age-Based Considerations

CCTA is preferable in patients <65 years of age who are not on optimal preventive therapies 1. The guidelines note that:

• Younger patients have lower likelihood of extensive coronary calcification that could limit image quality 2
• In patients ≥65 years, stress testing may be favored due to higher likelihood of ischemia 1
• Test choice should ultimately be guided by patient's exercise capacity and resting electrocardiographic abnormalities 1

Absolute Contraindications to CCTA

CCTA is not recommended in the following situations 2:

• Severe renal failure (eGFR <30 mL/min/1.73 m²)
• Decompensated heart failure
• Extensive coronary calcification
• Fast irregular heart rate
• Severe obesity
• Inability to cooperate with breath-hold commands
• Any condition making good imaging quality unlikely

Alternative Testing Options

While CCTA is preferred, stress imaging (stress echocardiography, PET/SPECT MPI, or CMR) remains effective for diagnosis of myocardial ischemia and estimating risk of MACE (Class I, Level B-R) 1. Consider stress imaging when:

• CCTA is contraindicated or unavailable 1
• Patient is ≥65 years with higher likelihood of ischemia 1
• Local expertise and availability favor functional testing 5

For patients with interpretable ECG and ability to achieve ≥5 METs of exercise, exercise electrocardiography is reasonable (Class 2a, Level B-R) 1, though it has lower diagnostic accuracy than CCTA or stress imaging 2.

Adjunctive Testing

Coronary artery calcium (CAC) scoring is reasonable as a first-line test for low-risk patients (Class 2a, Level B-R) to exclude calcified plaque and identify those with low likelihood of obstructive CAD 1. Additionally:

• CAC testing can be useful when added to stress testing in intermediate-high risk patients (Class 2a, Level B-NR) 1
• A CAC score of zero identifies a low-risk cohort who may not require additional diagnostic testing 5

Management Based on CCTA Results

No CAD (no stenosis or plaque):

• Continue preventive therapies 1
• No repeat testing needed for 2 years if no change in symptoms 5

Nonobstructive CAD (<50% stenosis):

• Optimize preventive therapies 1
• Consider stress testing if symptoms persist (Class 2a) 1

Obstructive CAD (≥50% stenosis):

• For stenosis 40%-90% in proximal or middle coronary segment, FFR-CT is useful for diagnosis of vessel-specific ischemia and guiding revascularization decisions (Class 2a, Level B-NR) 1, 5
• For high-risk CAD (left main ≥50% or 3-vessel disease ≥70%) or frequent angina, proceed to invasive coronary angiography (Class I) 1

Inconclusive CCTA:

• Stress imaging is reasonable as second-line testing (Class 2a, Level B-NR) 1

Common Pitfalls to Avoid

• Do not repeat the same functional test if it was previously inconclusive—CCTA is recommended instead to avoid repeat inconclusive results and enable definitive rule-out of obstructive CAD 5
• Do not order CCTA in patients with extensive coronary calcification, as this significantly limits diagnostic accuracy 2
• Do not use exercise ECG alone for diagnostic purposes in patients with ≥0.1 mV ST-segment depression on resting ECG, left bundle branch block, or digitalis therapy 2
• Recognize that normal stress testing may still harbor significant plaque burden, whereas normal CCTA has superior negative predictive value for future events 5

Clinical Outcomes Evidence

The SCOT-HEART trial demonstrated that CCTA-guided management led to long-term reduction in death and nonfatal myocardial infarction through increased use of preventive medical therapies, without increasing intervention rates 6. The PROMISE trial similarly showed that knowledge of plaque presence motivated patients to seek treatment and implement lifestyle changes 6.